ReviewPaediatric drugs2020
Recent Advances in the Pharmacological Management of Behavioral Disturbances Associated with Autism Spectrum Disorder in Children and Adolescents.
Review in Paediatric drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder.Scientific reports · 2023Trial
- Navigating the Complex Landscape of Autism Spectrum Disorder: Challenges and Opportunities in Diagnosis, Treatment, and Supports.Current pharmaceutical design · 2026Review
- Utilization of psychotropic medications in individuals with autism spectrum disorder.BMC psychiatry · 2025Article
- Effect of multispecies probiotics on autism symptoms: protocol for a randomized controlled trial (PROBAUT).Trials · 2025Article
- Neurexin1α knockout in rats causes aberrant social behaviour: relevance for autism and schizophrenia.Psychopharmacology · 2025Article
- Prevalence of Psychotropic Medication Use and Psychotropic Polypharmacy in Autistic Adults With or Without Intellectual Disability.Journal of autism and developmental disorders · 2025Article
- Article
- Article
- Cannabidiol is a behavioral modulator in BTBR mouse model of idiopathic autism.Frontiers in neuroscience · 2024Article
- Practical Aspects of ASD Management-What Pediatricians Should Know.Indian journal of pediatrics · 2023Review
- Striatal increase of dopamine receptor 2 density in idiopathic and syndromic mouse models of autism spectrum disorder.Frontiers in psychiatry · 2023Article
- Article
- Drug repurposing candidates to treat core symptoms in autism spectrum disorder.Frontiers in pharmacology · 2022Article
- Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder.Journal of autism and developmental disorders · 2021Article
- What is autism?Pharmacological reports : PR · 2021Review
- Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study.Children (Basel, Switzerland) · 2021Article
- Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children.Paediatric drugs · 2021Review
- Alterations of Regional Homogeneity in Preschool Boys With Autism Spectrum Disorders.Frontiers in neuroscience · 2021Article
- Neuroprotective Effects of Quercetin in Pediatric Neurological Diseases.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) is a heterogeneous neuropsychiatric condition affecting an estimated one in 36 children. Youth with ASD may have severe behavioral disturbances including irritability, aggression, and hyperactivity. Currently, there are only two medications (risperidone and aripiprazole) approved by the US Food and Drug Administration (FDA) for the treatment of irritability associated with ASD. Pharmacologic treatments are commonly used to target ASD-associated symptoms including irritability, mood lability, anxiety, and hyperactivity. However, evidence for the efficacy of many commonly used treatments is limited by the lack of large placebo-controlled trials of these medications in this population. Research into the pathophysiology of ASD has led to new targets for pharmacologic therapy including the neuroimmune system, the endocannabinoid system, and the glutamatergic neurotransmitter system. The goal of this review is to provide an overview of the current evidence base for commonly used treatments, as well as emerging treatment options for common behavioral disturbances seen in youth with ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.